NEW YORK – Genomind said today that it is expanding its year-old partnership with electronic health records developer DrChrono, allowing physicians to order the Genomind Professional PGx test directly through the EHR to support pharmacogenomics in mental health treatment. Doctors then can receive test results — usually within three days — and Genomind consultation services through the same portal.
King of Prussia, Pennsylvania-based Genomind has had a direct link to the DrChrono EHR platform since last year, but this expansion will support the Professional PGx Express test and offer services not previously available, including access to Genomind's Drug Interaction Guide the company said. These services are meant to support clinicians in ordering, receiving, and acting on information.
Also as part of the new agreement, users of the EHR from Sunnyvale, California-based DrChrono will be able to receive continuing medical education credit for taking an online Genomind course that teaches clinicians about the role pharmacogenomics and medication labels play in treating mental health conditions.
Genomind updated and rebranded its Genecept Assay as Professional PGx Express in August, expanding its mental health genetic testing services to help physicians navigate the connection between a patient's genetic biomarkers and their implications for mental health treatment. The firm noted that UnitedHealthcare recently issued a positive coverage decision for the use of multigene panel PGx testing, including Genomind's service, in certain patients being treated for major depressive disorder or anxiety.
The UnitedHealthcare policy includes a table of specific genes and drugs that have sufficient evidence according to the Clinical Pharmacogenetics Implementation Consortium to be actionable. This list, counter to the US Food and Drug Administration's position, cites CPIC guidelines on the impact of CYP2C19 on escitalopram and sertraline.
Also in August, Genomind reached an agreement with NeuroFlow to combine NeuroFlow's digital health platform with Genomind's genetic testing service. The aim of that collaboration is to improve patient wellness and reduce costs for conditions including depression, anxiety, post-traumatic stress disorder, and substance abuse.